STEMI – Medxy AI

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

By MedXY 02/08/2026

An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours.

Cardiology news

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

By MedXY 01/17/2026

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with comparable safety profiles between both regimens.

Cardiology news Psychiatry

Mental Health Labels Linked to Critical Delays and Doubled Five-Year Mortality in STEMI Care

By MedXY 01/03/2026

A prospective study reveals that patients with mental health conditions face significant delays in STEMI diagnosis, resulting in larger infarct sizes and a twofold increase in five-year cardiovascular mortality compared to those without such conditions.

Cardiology Emergency Medicine news

The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality

By MedXY 01/03/2026

A 20-year analysis of 89,155 patients from the SWEDEHEART registry confirms that pre-hospital delay independently predicts short- and long-term mortality. Despite advances in reperfusion, women, elderly patients, and those with diabetes consistently experience significantly longer delays, highlighting a critical need for targeted public health interventions.

Cardiology news Radiology

Post-PCI Troponin Kinetics Reveal Hemorrhagic Transformation as a Critical Driver of In-Hospital Mortality in STEMI

By MedXY 12/31/2025

A multicenter study identifies high-sensitivity troponin I kinetics as a diagnostic marker for hemorrhagic myocardial infarction, linking this reperfusion injury to a nearly threefold increase in the risk of in-hospital mortality following primary percutaneous coronary intervention.

Cardiology Critical Care news

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS

By MedXY 12/31/2025

This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial's profile have significantly better survival outcomes when treated with microaxial flow pumps compared to those who do not meet these specific clinical markers.

Cardiology Critical Care news

Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock

By MedXY 12/31/2025

Recent substudies from the DanGer Shock trial demonstrate that microaxial flow pumps significantly improve hemodynamics, accelerate lactate clearance, and reduce vasopressor needs in STEMI-related cardiogenic shock, though sex-specific outcomes are heavily influenced by age and treatment delays.

Cardiology Internal Medicine news

Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial

By MedXY 12/24/2025

This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of aggressive lipid management in secondary prevention.

Cardiology news

Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding

By MedXY 11/13/2025

In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with more mild–moderate bleeding but no increase in severe bleeding.

Cardiology news

Immediate vs Deferred PCI for Nonculprit Lesions in STEMI: Insights from the iMODERN Trial

By MedXY 10/31/2025

The iMODERN trial demonstrates that immediate iFR-guided PCI of nonculprit lesions in STEMI patients offers no significant benefit over deferred stress MRI-guided PCI regarding major cardiac events at 3 years.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Cardiology news Specialties

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial

By MedXY 09/21/2025

The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.

Cardiology Specialties

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

By MedXY 08/17/2025

The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.

Cardiology news Specialties

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial

By MedXY 08/13/2025

The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers' superiority.